Engineering Hybrid SynNotch CAR Receptors to Enhance Cell Therapies for Cancer
工程设计混合 SynNotch CAR 受体以增强癌症细胞疗法
基本信息
- 批准号:10576297
- 负责人:
- 金额:$ 4.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAntigensArchitectureB-LymphocytesBindingCAR T cell therapyCD8B1 geneCaliforniaCancerousCell TherapyCell membraneCell physiologyCellsComplexCustomCytotoxic T-LymphocytesDataDefectEngineeringEnvironmentEnzymesExtracellular DomainFaceFunctional disorderFutureGenerationsGeneticGenetic TranscriptionGraduate EducationHybridsITAMImmunologyImmunotherapeutic agentInhibition of Cell ProliferationInstitutionInterleukin-2Interleukin-6LigandsLiquid substanceMalignant NeoplasmsManuscriptsMentorshipMultiple MyelomaNutrientOxygenPatientsProductionProgram DevelopmentProliferatingPublishingRefractoryRelapseResearch PersonnelResourcesResponse ElementsSan FranciscoScienceSignal TransductionSolidT cell therapyT-Cell ActivationT-Cell ReceptorT-LymphocyteTailTherapeuticTrainingTranscriptional ActivationTranscriptional RegulationTransmembrane DomainTumor AntigensUniversitiesWorkWritingantigen bindingcancer cellcancer immunotherapycancer therapycancer typecareercell growthcell killingchimeric antigen receptorchimeric antigen receptor T cellscytokinecytotoxicityengineered T cellsexhaustionextracellulargraduate studentneoplastic cellnotch proteinnovelprogramsreceptorrefractory cancerresponsetranscription factortumortumor microenvironmenttumor-immune system interactions
项目摘要
Chimeric Antigen T Cell (CAR-T) therapies, which redirect a patient’s own T cells towards their cancer,
are very promising therapies for difficult to treat and refractory cancers. While CAR T cell therapies have been
very successful in treating refractory B cell cancers,1,2 they have encountered many challenges when directed
towards more complex solid and liquid tumors, such as multiple myeloma. CAR T cells face challenges such as
an immunosuppressive tumor microenvironment, in which inhibitory ligands are often expressed, nutrients and
oxygen are lacking, and cytokines or soluble factors are secreted to support malignant cell growth.3 This hostile
environment, as well as cell intrinsic defects, can lead to reduced CAR T cell proliferation, inhibition of function
and loss of CAR T cell persistence. Previously developed synthetic Notch (synNotch) receptors allow for control
and customization of therapeutic immune cells.4,5,6 SynNotch T cells can deliver user defined cell intrinsic or
extrinsic payloads, such as transcription factors, cytokines, or antibodies in an antigen specific, spatially
controlled manner. While these receptor circuits could be used to address the many challenges of complex
tumors, these receptors lack the ability to initiate cytotoxicity like CARs or TCRs. Therefore, successful and
persistent engineered T cells require both the ability to recognize, activate and kill tumor cells, as well as the
ability to produce payloads to counteract a wide range of challenges encountered in challenging tumor
microenvironments. Recently, I have engineered a novel “Hybrid SynNotch CAR” receptor, whose architecture
incorporates signaling domains (e.g. co-stimulation, CD3z, etc.) that can initiate activation of T cells concomitant
with custom transcriptional regulation typical of a SynNotch receptor. These Hybrid synNotch CAR receptors are
functional and represent a new class of synthetic receptors that activate short timescale signaling and long term
custom transcriptional responses in a single receptor architecture. This proposal seeks to expand upon these
initial proof-of-concept Hybrid SynNotch CAR receptors, understanding their full range of function and effect on
engineered T cells, and demonstrating their ability to address therapeutic challenges in multiple myeloma.
The University of California, San Francisco (UCSF) is a leading institution in immunology and is regarded
as one of the top doctoral programs in Biomedical Sciences graduate education. As a graduate student in the
Roybal lab, I receive regular guidance and mentorship from renowned investigators and have access to
resources provided by the Parker Institute for Cancer Immunotherapy, and the Chan Zuckerberg Biohub. This
training plan also includes commitment to professional development programs, such as the UCSF TRAIN UP
Mentorship program, and courses in manuscript and thesis writing. This proposal seeks to develop and apply a
novel synthetic receptor circuit, which simultaneously targets cancer cells and addresses diverse challenges in
tumors and tumor microenvironments. Completion of the proposed work will move the field of engineered cancer
immunotherapy forward and prepare me for a future career as an independent investigator.
嵌合抗原T细胞(CAR-T)疗法,将患者自身的T细胞转向癌症,
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Julie Marie Garcia其他文献
Julie Marie Garcia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Julie Marie Garcia', 18)}}的其他基金
Engineering Hybrid SynNotch CAR Receptors to Enhance Cell Therapies for Cancer
工程设计混合 SynNotch CAR 受体以增强癌症细胞疗法
- 批准号:
10229224 - 财政年份:2021
- 资助金额:
$ 4.31万 - 项目类别:
Engineering Hybrid SynNotch CAR Receptors to Enhance Cell Therapies for Cancer
工程设计混合 SynNotch CAR 受体以增强癌症细胞疗法
- 批准号:
10364646 - 财政年份:2021
- 资助金额:
$ 4.31万 - 项目类别:
相似海外基金
Rationally guided discovery platform for monoclonal antibodies against carbohydrate antigens using virus-like particle conjugate immunization and high throughput selection
使用病毒样颗粒缀合物免疫和高通量选择的合理引导的针对碳水化合物抗原的单克隆抗体的发现平台
- 批准号:
10574738 - 财政年份:2023
- 资助金额:
$ 4.31万 - 项目类别:
Assessing the role of liver stage antigens-specific antibodies against Plasmodium falciparum liver stage infection
评估肝期抗原特异性抗体对抗恶性疟原虫肝期感染的作用
- 批准号:
10392870 - 财政年份:2021
- 资助金额:
$ 4.31万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
10092930 - 财政年份:2020
- 资助金额:
$ 4.31万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
9896170 - 财政年份:2020
- 资助金额:
$ 4.31万 - 项目类别:
Interrogation of cell surface antigens on B lineage cells using structurally unique variable lymphocyte receptor antibodies of the evolutionarily distant sea lamprey
使用进化遥远的海七鳃鳗结构独特的可变淋巴细胞受体抗体询问 B 谱系细胞上的细胞表面抗原
- 批准号:
433456 - 财政年份:2020
- 资助金额:
$ 4.31万 - 项目类别:
Operating Grants
Investigations of interactions between various natural antibodies and food-derived antigens
研究各种天然抗体与食物源性抗原之间的相互作用
- 批准号:
19K15765 - 财政年份:2019
- 资助金额:
$ 4.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying Kawasaki Disease-Specific Antibodies and Antigens
识别川崎病特异性抗体和抗原
- 批准号:
9932769 - 财政年份:2018
- 资助金额:
$ 4.31万 - 项目类别:
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
BB/P504713/1 - 财政年份:2017
- 资助金额:
$ 4.31万 - 项目类别:
Training Grant
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
1932904 - 财政年份:2017
- 资助金额:
$ 4.31万 - 项目类别:
Studentship
SBIR Phase II: Automated Design Methods of Antibodies Directed to Protein and Carbohydrate Antigens
SBIR II 期:针对蛋白质和碳水化合物抗原的抗体的自动化设计方法
- 批准号:
1632399 - 财政年份:2016
- 资助金额:
$ 4.31万 - 项目类别:
Standard Grant